.png){kind=logo}
Stock image for illustration purposes only - book cover, edition or condition may vary.
Epigenetics and Disease
. Ed(S): Gasser, Susan M.; Li, En
€ 249.16
FREE Delivery in Ireland
Description for Epigenetics and Disease
Paperback. Epigentic alterations, unlike genetic, are, in principle, amenable to pharmacological intervention, and a few of those drugs are currently undergoing clinical trial. This volume highlights the results of those studies. Editor(s): Gasser, Susan M.; Li, En. Series: Progress in Drug Research. Num Pages: 280 pages, biography. BIC Classification: MFN. Category: (P) Professional & Vocational. Dimension: 235 x 155 x 15. Weight in Grams: 433.
Epigenetics has emerged recently as an important area of molecular biological studies. Epigenetic modifications lead to potentially heritable but reversible alterations in the expression of genes that determine cell fate. Epigenetic misregulation is thus often linked to degenerative diseases, cancer and neuronal disorders. Recent biomedical interest in this regulatory system stems from the fact that epigenetic, in contrast to genetic, alterations are in principle amenable to pharmacological intervention. A few epigenetically active drugs, for example histone deacetylase inhibitors (HDACi) and DNA methyltransferase (DNMT) inhibitors, have been approved by FDA for treatment of cancers such as CTCL, MDS, and AML. This ... Read more
Epigenetics has emerged recently as an important area of molecular biological studies. Epigenetic modifications lead to potentially heritable but reversible alterations in the expression of genes that determine cell fate. Epigenetic misregulation is thus often linked to degenerative diseases, cancer and neuronal disorders. Recent biomedical interest in this regulatory system stems from the fact that epigenetic, in contrast to genetic, alterations are in principle amenable to pharmacological intervention. A few epigenetically active drugs, for example histone deacetylase inhibitors (HDACi) and DNA methyltransferase (DNMT) inhibitors, have been approved by FDA for treatment of cancers such as CTCL, MDS, and AML. This ... Read more
Product Details
Format
Paperback
Publication date
2012
Publisher
Springer Basel Switzerland
Number of pages
280
Condition
New
Series
Progress in Drug Research
Number of Pages
270
Place of Publication
, Switzerland
ISBN
9783034803052
SKU
V9783034803052
Shipping Time
Usually ships in 15 to 20 working days
Ref
99-15
Reviews for Epigenetics and Disease